Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Viramidine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Viramidine | DRUG | - |
| Ribavirin | DRUG | - |
| pegylated interferon alfa-2a | DRUG | - |
| pegylated interferon alfa-2b | DRUG | - |
Inclusion Criteria: * Treatment-naive patients with compensated chronic hepatitis C. * HCV RNA \>2000 copies/mL (780 IU/mL) as determined by NGI SuperQuant serum HCV RNA quantification, with a lower limit of detection of 100 copies/mL (39 IU/mL). Exclusion Criteria: * Severe neuropsychiatric diso...
Viramidine is an investigational small molecule being studied for the treatment of chronic Hepatitis C. It is a nucleoside analogue that was evaluated in Phase 3 clinical trials as a potential alternative to ribavirin in patients with chronic Hepatitis C who are treatment naive.
Viramidine is being developed by Bausch Health Companies Inc., which trades under the ticker symbol BHC on the stock market. The company has conducted clinical trials to evaluate the drug's safety and efficacy in patients with chronic Hepatitis C.
Viramidine is in Phase 3 clinical development. It has completed two Phase 3 trials, but it is not yet approved by regulatory authorities. The drug remains investigational and is not available for commercial use.
Viramidine has been studied in two completed Phase 3 clinical trials. The first trial, NCT00093093, enrolled 900 treatment-naive patients with chronic Hepatitis C across multiple countries. The second trial, NCT00230958, also enrolled 900 treatment-naive patients with the same condition.
No, Viramidine is not the same as ribavirin, but it was studied as a comparison to ribavirin in clinical trials. Both are small molecules used for chronic Hepatitis C, but Viramidine is a distinct investigational compound being evaluated as a potential alternative.